Ser16
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser16  -  PLB (mouse)

Site Information
RSAIRRAstIEMPQQ   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448114

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 63 ) , immunoprecipitation ( 59 ) , mass spectrometry ( 8 , 14 , 18 , 19 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 ) , mutation of modification site ( 9 , 10 , 20 , 55 , 57 , 59 ) , peptide sequencing ( 63 ) , phospho-antibody ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 9 , 10 , 11 , 12 , 13 , 16 , 20 , 31 , 32 , 54 , 55 , 56 , 58 , 59 , 60 , 61 , 62 ) , phosphoamino acid analysis ( 63 ) , phosphopeptide mapping ( 63 ) , western blotting ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 9 , 10 , 11 , 12 , 13 , 16 , 20 , 31 , 32 , 54 , 55 , 56 , 58 , 60 )
Relevant cell line - cell type - tissue:
'muscle, smooth' ( 54 ) , 293 (epithelial) ( 7 , 10 ) , cardiac-heart ( 4 , 10 ) , heart ( 1 , 2 , 3 , 9 , 11 , 14 , 16 , 18 , 19 , 23 , 24 , 27 , 28 , 29 , 30 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 49 , 50 , 51 , 52 , 53 , 56 , 58 , 63 ) , heart [PLB (mouse)] ( 61 , 62 ) , heart [RYR2 (mouse), genetic knockin] ( 20 ) , HL-1 (myocyte) [Akt1 (mouse), knockdown, stable lentiviral expression of Akt1 shRNA] ( 8 ) , HL-1 (myocyte) [Akt2 (mouse), knockdown, stable lentiviral expression of Akt2 shRNA] ( 8 ) , HL-1 (myocyte) ( 8 ) , kidney ( 19 ) , liver ( 25 , 26 ) , lung ( 19 ) , myocyte-heart ( 5 , 6 , 12 , 13 , 32 , 55 , 57 , 59 ) , myocyte-heart [PLB (mouse), genetic knockin] ( 57 ) , myocyte-heart [PLB (mouse), homozygous knockout] ( 57 ) , myocyte-heart [PMCA4 iso2 (human), transgenic] ( 31 ) , myocyte-heart [SERCA2 (mouse), transfection] ( 60 ) , thymus ( 21 , 22 )

Upstream Regulation
Regulatory protein:
ADRB1 (mouse) ( 14 ) , CAMK2D (mouse) ( 58 ) , H2R (mouse) ( 2 ) , plakophilin 2 (mouse) ( 3 ) , PMCA4 iso2 (human) ( 31 ) , PPP5C (human) ( 1 ) , SERCA2 (mouse) ( 60 ) , Spinophilin (mouse) ( 10 ) , TPM1 (mouse) ( 13 , 17 )
Kinases, in vitro:
CAMK2A (mouse) ( 59 ) , PKACA (mouse) ( 15 , 59 )
Putative upstream phosphatases:
PPP2CA (human) ( 1 )
Treatments:
adriamycin ( 5 ) , amitriptyline ( 2 ) , autocamtide_inhibitory_peptide ( 11 , 56 ) , bisindolylmaleimide ( 32 ) , cGMP_analog ( 54 ) , cpTOME ( 32 ) , cyclopiazonic_acid ( 54 ) , dobutamine ( 56 ) , electrical_stimulation ( 55 ) , H-89 ( 7 ) , high-fat diet ( 6 ) , histamine ( 2 ) , IBMX ( 7 ) , inhibitor-1 ( 16 ) , isoproterenol ( 4 , 6 , 7 , 12 , 31 , 59 , 63 ) , KN-93 ( 54 ) , NKH_477 ( 7 ) , ODQ ( 54 ) , SNP ( 54 ) , wheel running test ( 3 )

Downstream Regulation
Effects of modification on PLB:
activity, induced ( 57 ) , molecular association, regulation ( 15 ) , protein degradation ( 7 )
Inhibit interaction with:
PPP1R3A (mouse) ( 15 )

References 

1

Dörner MF, et al. (2021) Mechanisms of Systolic Cardiac Dysfunction in PP2A, PP5 and PP2AxPP5 Double Transgenic Mice. Int J Mol Sci 22
34502355   Curated Info

2

Neumann J, et al. (2021) Amitriptyline functionally antagonizes cardiac H histamine receptors in transgenic mice and human atria. Naunyn Schmiedebergs Arch Pharmacol
33625558   Curated Info

3

Hammer KP, et al. (2021) Beneficial effect of voluntary physical exercise in Plakophilin2 transgenic mice. PLoS One 16, e0252649
34086773   Curated Info

4

Werhahn SM, et al. (2021) Adaptive versus maladaptive cardiac remodelling in response to sustained β-adrenergic stimulation in a new 'ISO on/off model'. PLoS One 16, e0248933
34138844   Curated Info

5

Llach A, et al. (2019) Progression of excitation-contraction coupling defects in doxorubicin cardiotoxicity. J Mol Cell Cardiol 126, 129-139
30500377   Curated Info

6

Fu Q, et al. (2017) High-fat diet induces protein kinase A and G-protein receptor kinase phosphorylation of β2 -adrenergic receptor and impairs cardiac adrenergic reserve in animal hearts. J Physiol 595, 1973-1986
27983752   Curated Info

7

Nakagawa T, Yokoe S, Asahi M (2016) Phospholamban degradation is induced by phosphorylation-mediated ubiquitination and inhibited by interaction with cardiac type Sarco(endo)plasmic reticulum Ca(2+)-ATPase. Biochem Biophys Res Commun 472, 523-30
26966065   Curated Info

8

Reinartz M, Raupach A, Kaisers W, Gödecke A (2014) AKT1 and AKT2 induce distinct phosphorylation patterns in HL-1 cardiac myocytes. J Proteome Res 13, 4232-45
25162660   Curated Info

9

Di Carlo MN, et al. (2014) CaMKII-dependent phosphorylation of cardiac ryanodine receptors regulates cell death in cardiac ischemia/reperfusion injury. J Mol Cell Cardiol 74, 274-83
24949568   Curated Info

10

Chiang DY, et al. (2014) Impaired local regulation of ryanodine receptor type 2 by protein phosphatase 1 promotes atrial fibrillation. Cardiovasc Res 103, 178-87
24812280   Curated Info

11

Chakraborty A, et al. (2014) Inhibition of CaMKII Does Not Attenuate Cardiac Hypertrophy in Mice with Dysfunctional Ryanodine Receptor. PLoS One 9, e104338
25093823   Curated Info

12

Besser J, et al. (2014) MiRNA-1/133a Clusters Regulate Adrenergic Control of Cardiac Repolarization. PLoS One 9, e113449
25415383   Curated Info

13

Schulz EM, et al. (2013) Decreasing Tropomyosin Phosphorylation Rescues Tropomyosin-induced Familial Hypertrophic Cardiomyopathy. J Biol Chem 288, 28925-28935
23960072   Curated Info

14

Lundby A, et al. (2013) In vivo phosphoproteomics analysis reveals the cardiac targets of β-adrenergic receptor signaling. Sci Signal 6, rs11
23737553   Curated Info

15

Vafiadaki E, Arvanitis DA, Sanoudou D, Kranias EG (2013) Identification of a protein phosphatase-1/phospholamban complex that is regulated by cAMP-dependent phosphorylation. PLoS One 8, e80867
24244723   Curated Info

16

Pritchard TJ, et al. (2013) Active inhibitor-1 maintains protein hyper-phosphorylation in aging hearts and halts remodeling in failing hearts. PLoS One 8, e80717
24312496   Curated Info

17

Schulz EM, et al. (2012) Tropomyosin dephosphorylation results in compensated cardiac hypertrophy. J Biol Chem 287, 44478-89
23148217   Curated Info

18

Deng N, et al. (2011) Phosphoproteome analysis reveals regulatory sites in major pathways of cardiac mitochondria. Mol Cell Proteomics 10, M110.000117
20495213   Curated Info

19

Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89
21183079   Curated Info

20

Sarma S, et al. (2010) Genetic inhibition of PKA phosphorylation of RyR2 prevents dystrophic cardiomyopathy. Proc Natl Acad Sci U S A 107, 13165-70
20615971   Curated Info

21

Guo A (2009) CST Curation Set: 8170; Year: 2009; Biosample/Treatment: tissue, thymus/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

22

Guo A (2009) CST Curation Set: 8169; Year: 2009; Biosample/Treatment: tissue, thymus/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

23

Zhou J (2009) CST Curation Set: 7444; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

24

Zhou J (2009) CST Curation Set: 7445; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

25

Zhou J (2009) CST Curation Set: 7426; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST]
Curated Info

26

Zhou J (2009) CST Curation Set: 7425; Year: 2009; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST]
Curated Info

27

Zhou J (2009) CST Curation Set: 7417; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST]
Curated Info

28

Zhou J (2009) CST Curation Set: 7418; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST]
Curated Info

29

Zhou J (2009) CST Curation Set: 7385; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST]
Curated Info

30

Zhou J (2009) CST Curation Set: 7386; Year: 2009; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: QXp[ST]
Curated Info

31

Mohamed TM, et al. (2009) Specific role of neuronal nitric-oxide synthase when tethered to the plasma membrane calcium pump in regulating the beta-adrenergic signal in the myocardium. J Biol Chem 284, 12091-8
19278978   Curated Info

32

Oestreich EA, et al. (2009) Epac and phospholipase Cepsilon regulate Ca2+ release in the heart by activation of protein kinase Cepsilon and calcium-calmodulin kinase II. J Biol Chem 284, 1514-22
18957419   Curated Info

33

Stokes M (2008) CST Curation Set: 5664; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

34

Stokes M (2008) CST Curation Set: 5665; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

35

Stokes M (2008) CST Curation Set: 5168; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS*/T*) Immunoaffinity Beads Cat#: 1984
Curated Info

36

Stokes M (2008) CST Curation Set: 5087; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

37

Stokes M (2008) CST Curation Set: 5088; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

38

Stokes M (2008) CST Curation Set: 5089; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

39

Stokes M (2008) CST Curation Set: 5090; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

40

Stokes M (2008) CST Curation Set: 5091; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

41

Stokes M (2008) CST Curation Set: 5092; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

42

Stokes M (2008) CST Curation Set: 5093; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

43

Stokes M (2008) CST Curation Set: 5094; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

44

Zhou J (2008) CST Curation Set: 4782; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

45

Rikova K (2008) CST Curation Set: 4776; Year: 2008; Biosample/Treatment: cell line, Dana Farber-KTL(LN)-4/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

46

Rikova K (2008) CST Curation Set: 4772; Year: 2008; Biosample/Treatment: cell line, Dana Farber-KTL-1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

47

Rikova K (2008) CST Curation Set: 4760; Year: 2008; Biosample/Treatment: cell line, Dana Farber-L1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

48

Rikova K (2008) CST Curation Set: 4762; Year: 2008; Biosample/Treatment: cell line, Dana Farber-L2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

49

Possemato A (2008) CST Curation Set: 3820; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PKD Substrate Antibody Cat#: 4381, PTMScan(R) Phospho-PKD Substrate Motif (LXRXXpS/pT) Immunoaffinity Beads Cat#: 1986
Curated Info

50

Possemato A (2008) CST Curation Set: 3830; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RRXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-PKA Substrate (RRXS/T) (100G7) Rabbit mAb Cat#: 9624, PTMScan(R) Phospho-PKA Substrate Motif (K/RK/RXS*/T*) Immunoaffinity Beads Cat#: 1984
Curated Info

51

Guo A (2007) CST Curation Set: 3118; Year: 2007; Biosample/Treatment: tissue, heart/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y)p[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) PDK1 Docking Motif (18A2) Mouse mAb Cat#: 9634, PTMScan(R) Phospho-PDK1 Docking Motif (F/YS*/T*F/Y) Immunoaffinity Beads Cat#: 1992
Curated Info

52

Guo A (2007) CST Curation Set: 2923; Year: 2007; Biosample/Treatment: tissue, heart/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](D/E)X(D/E) Antibodies Used to Purify Peptides prior to LCMS: Phospho(Ser/Thr) CKII Substrate Antibody (polyAb) Cat#: 5808, PTMScan(R) Phospho-CK Substrate Motif (S*/T*D/EXD/E) Immunoaffinity Beads Cat#: 1994
Curated Info

53

Guo A (2007) CST Curation Set: 2829; Year: 2007; Biosample/Treatment: tissue, heart/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

54

Kim M, Perrino BA (2007) CaM kinase II activation and phospholamban phosphorylation by SNP in murine gastric antrum smooth muscles. Am J Physiol Gastrointest Liver Physiol 292, G1045-54
17185633   Curated Info

55

Zhao W, et al. (2004) Threonine-17 phosphorylation of phospholamban: a key determinant of frequency-dependent increase of cardiac contractility. J Mol Cell Cardiol 37, 607-12
15276030   Curated Info

56

Ji Y, et al. (2003) Targeted inhibition of Ca2+/calmodulin-dependent protein kinase II in cardiac longitudinal sarcoplasmic reticulum results in decreased phospholamban phosphorylation at threonine 17. J Biol Chem 278, 25063-71
12692124   Curated Info

57

Li Y, Kranias EG, Mignery GA, Bers DM (2002) Protein kinase A phosphorylation of the ryanodine receptor does not affect calcium sparks in mouse ventricular myocytes. Circ Res 90, 309-16
11861420   Curated Info

58

Zhang T, et al. (2002) The cardiac-specific nuclear delta(B) isoform of Ca2+/calmodulin-dependent protein kinase II induces hypertrophy and dilated cardiomyopathy associated with increased protein phosphatase 2A activity. J Biol Chem 277, 1261-7
11694533   Curated Info

59

Chu G, et al. (2000) A single site (Ser16) phosphorylation in phospholamban is sufficient in mediating its maximal cardiac responses to beta -agonists. J Biol Chem 275, 38938-43
10988285   Curated Info

60

Ji Y, et al. (2000) Disruption of a single copy of the SERCA2 gene results in altered Ca2+ homeostasis and cardiomyocyte function. J Biol Chem 275, 38073-80
10970890   Curated Info

61

Mayer EJ, Huckle W, Johnson RG, McKenna E (2000) Characterization and quantitation of phospholamban and its phosphorylation state using antibodies. Biochem Biophys Res Commun 267, 40-8
10623571   Curated Info

62

Mayer EJ, Savage GM, Johnson RG (1998) A quantitative immunoassay for the measurement of phospholamban levels and phosphorylation states. Measurement of phospholamban levels in transgenic mouse hearts. Ann N Y Acad Sci 853, 284-7
10603960   Curated Info

63

Wegener AD, Simmerman HK, Lindemann JP, Jones LR (1989) Phospholamban phosphorylation in intact ventricles. Phosphorylation of serine 16 and threonine 17 in response to beta-adrenergic stimulation. J Biol Chem 264, 11468-74
2544595   Curated Info